1. Preface
1.1. Report Description
1.1.1. Purpose of the Report
1.1.2. Target Audience
1.1.3. Key Offerings
1.2. Market Segmentation
1.3. Research Methodology
1.3.1. Phase I - Secondary Research
1.3.2. Phase II - Primary Research
1.3.3. Phase III - Expert Panel Review
1.3.4. Assumptions
1.3.5. Approach Adopted

2. Executive Summary
2.1. Market Snapshot: Global Tuberculosis Diagnostics Market
2.2. Global Tuberculosis Diagnostics Market, By Test, 2023 (US$ Million)
2.3. Global Tuberculosis Diagnostics Market, By Geography, 2023 (US$ Million)
2.4. Attractive Investment Proposition by Geography, 2023

3. Tuberculosis Diagnostics Market: Competitive Analysis
3.1. Market Positioning of Key Tuberculosis Diagnostics Market Vendors
3.2. Strategies Adopted by Tuberculosis Diagnostics Market Vendors
3.3. Key Industry Strategies
3.4. Tier Analysis 2023 Versus 2032

4. Tuberculosis Diagnostics Market: Macro Analysis & Market Dynamics
4.1. Introduction
4.2. Global Tuberculosis Diagnostics Market Value, 2022 - 2032, (US$ Million)
4.3. Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Key Challenges
4.3.4. Key Opportunities
4.4. Impact Analysis of Drivers and Restraints
4.5. See-Saw Analysis
4.6. Porter's Five Force Model
4.6.1. Supplier Power
4.6.2. Buyer Power
4.6.3. Threat Of Substitutes
4.6.4. Threat Of New Entrants
4.6.5. Competitive Rivalry
4.7. PESTEL Analysis
4.7.1. Political Landscape
4.7.2. Economic Landscape
4.7.3. Technology Landscape
4.7.4. Legal Landscape
4.7.5. Social Landscape

5. Tuberculosis Diagnostics Market: By Test, 2022-2032, USD (Million)
5.1. Market Overview
5.2. Growth & Revenue Analysis: 2023 Versus 2032
5.3. Market Segmentation
5.3.1. Radiographic Methods
5.3.2. Laboratory Methods
5.3.2.1. Smear Microscopy
5.3.2.2. Culture Based Test
5.3.3. Nucleic Acid Testing
5.3.4. Phage Assay
5.3.5. Cytokine Detection Test
5.3.6. Detection of Drug Resistance
5.3.7. Mantoux Test


6. North America Tuberculosis Diagnostics Market, 2022-2032, USD (Million)
6.1. Market Overview
6.2. Tuberculosis Diagnostics Market: By Test, 2022-2032, USD (Million)
6.3.Tuberculosis Diagnostics Market: By Region, 2022-2032, USD (Million)
6.3.1.North America
6.3.1.1. U.S.
6.3.1.1.1. Tuberculosis Diagnostics Market: By Test, 2022-2032, USD (Million)
6.3.1.2. Canada
6.3.1.2.1. Tuberculosis Diagnostics Market: By Test, 2022-2032, USD (Million)
6.3.1.3. Rest of North America
6.3.1.3.1. Tuberculosis Diagnostics Market: By Test, 2022-2032, USD (Million)

7. UK and European Union Tuberculosis Diagnostics Market, 2022-2032, USD (Million)
7.1. Market Overview
7.2. Tuberculosis Diagnostics Market: By Test, 2022-2032, USD (Million)
7.3.Tuberculosis Diagnostics Market: By Region, 2022-2032, USD (Million)
7.3.1.UK and European Union
7.3.1.1. UK
7.3.1.1.1. Tuberculosis Diagnostics Market: By Test, 2022-2032, USD (Million)
7.3.1.2. Germany
7.3.1.2.1. Tuberculosis Diagnostics Market: By Test, 2022-2032, USD (Million)
7.3.1.3. Spain
7.3.1.3.1. Tuberculosis Diagnostics Market: By Test, 2022-2032, USD (Million)
7.3.1.4. Italy
7.3.1.4.1. Tuberculosis Diagnostics Market: By Test, 2022-2032, USD (Million)
7.3.1.5. France
7.3.1.5.1. Tuberculosis Diagnostics Market: By Test, 2022-2032, USD (Million)
7.3.1.6. Rest of Europe
7.3.1.6.1. Tuberculosis Diagnostics Market: By Test, 2022-2032, USD (Million)

8. Asia Pacific Tuberculosis Diagnostics Market, 2022-2032, USD (Million)
8.1. Market Overview
8.2. Tuberculosis Diagnostics Market: By Test, 2022-2032, USD (Million)
8.3.Tuberculosis Diagnostics Market: By Region, 2022-2032, USD (Million)
8.3.1.Asia Pacific
8.3.1.1. China
8.3.1.1.1. Tuberculosis Diagnostics Market: By Test, 2022-2032, USD (Million)
8.3.1.2. Japan
8.3.1.2.1. Tuberculosis Diagnostics Market: By Test, 2022-2032, USD (Million)
8.3.1.3. India
8.3.1.3.1. Tuberculosis Diagnostics Market: By Test, 2022-2032, USD (Million)
8.3.1.4. Australia
8.3.1.4.1. Tuberculosis Diagnostics Market: By Test, 2022-2032, USD (Million)
8.3.1.5. South Korea
8.3.1.5.1. Tuberculosis Diagnostics Market: By Test, 2022-2032, USD (Million)
8.3.1.6. Rest of Asia Pacific
8.3.1.6.1. Tuberculosis Diagnostics Market: By Test, 2022-2032, USD (Million)

9. Latin America Tuberculosis Diagnostics Market, 2022-2032, USD (Million)
9.1. Market Overview
9.2. Tuberculosis Diagnostics Market: By Test, 2022-2032, USD (Million)
9.3.Tuberculosis Diagnostics Market: By Region, 2022-2032, USD (Million)
9.3.1.Latin America
9.3.1.1. Brazil
9.3.1.1.1. Tuberculosis Diagnostics Market: By Test, 2022-2032, USD (Million)
9.3.1.2. Mexico
9.3.1.2.1. Tuberculosis Diagnostics Market: By Test, 2022-2032, USD (Million)
9.3.1.3. Rest of Latin America
9.3.1.3.1. Tuberculosis Diagnostics Market: By Test, 2022-2032, USD (Million)

10. Middle East and Africa Tuberculosis Diagnostics Market, 2022-2032, USD (Million)
10.1. Market Overview
10.2. Tuberculosis Diagnostics Market: By Test, 2022-2032, USD (Million)
10.3.Tuberculosis Diagnostics Market: By Region, 2022-2032, USD (Million)
10.3.1.Middle East and Africa
10.3.1.1. GCC
10.3.1.1.1. Tuberculosis Diagnostics Market: By Test, 2022-2032, USD (Million)
10.3.1.2. Africa
10.3.1.2.1. Tuberculosis Diagnostics Market: By Test, 2022-2032, USD (Million)
10.3.1.3. Rest of Middle East and Africa
10.3.1.3.1. Tuberculosis Diagnostics Market: By Test, 2022-2032, USD (Million)

11. Company Profile
11.1. Abbott Laboratories
11.1.1. Company Overview
11.1.2. Financial Performance
11.1.3. Product Portfolio
11.1.4. Strategic Initiatives
11.2. Alere, Inc.
11.2.1. Company Overview
11.2.2. Financial Performance
11.2.3. Product Portfolio
11.2.4. Strategic Initiatives
11.3. Becton Dickinson and Company
11.3.1. Company Overview
11.3.2. Financial Performance
11.3.3. Product Portfolio
11.3.4. Strategic Initiatives
11.4. bioMérieux SA
11.4.1. Company Overview
11.4.2. Financial Performance
11.4.3. Product Portfolio
11.4.4. Strategic Initiatives
11.5. Cepheid Inc.
11.5.1. Company Overview
11.5.2. Financial Performance
11.5.3. Product Portfolio
11.5.4. Strategic Initiatives
11.6. Epistem plc
11.6.1. Company Overview
11.6.2. Financial Performance
11.6.3. Product Portfolio
11.6.4. Strategic Initiatives
11.7. F. Hoffman La Roche AG
11.7.1. Company Overview
11.7.2. Financial Performance
11.7.3. Product Portfolio
11.7.4. Strategic Initiatives
11.8. Hain Lifescience GmbH
11.8.1. Company Overview
11.8.2. Financial Performance
11.8.3. Product Portfolio
11.8.4. Strategic Initiatives
11.9. Hologic Corporation
11.9.1. Company Overview
11.9.2. Financial Performance
11.9.3. Product Portfolio
11.9.4. Strategic Initiatives
11.10. Thermo Fisher Scientific, Inc.
11.10.1. Company Overview
11.10.2. Financial Performance
11.10.3. Product Portfolio
11.10.4. Strategic Initiatives
11.11. QIAGEN
11.11.1. Company Overview
11.11.2. Financial Performance
11.11.3. Product Portfolio
11.11.4. Strategic Initiatives